1239596-54-3

Usage

Uses

Used in Pharmaceutical Industry:
3,3-Difluoro-4-hydroxypiperidine is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs. Its unique structure with fluorine atoms and a hydroxyl group makes it a valuable building block in medicinal chemistry for enhancing the properties of drug candidates.
Used in Agrochemical Industry:
In the agrochemical sector, 3,3-Difluoro-4-hydroxypiperidine serves as an intermediate in the synthesis of agrochemicals, aiding in the development of effective and novel compounds for agricultural applications.
Used in Organic Synthesis:
3,3-Difluoro-4-hydroxypiperidine is employed as a building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used as a Reagent in Chemical Research:
3,3-Difluoro-4-hydroxypiperidine is also used as a reagent in chemical research, facilitating various experimental procedures and contributing to the advancement of scientific knowledge in chemistry.
Used as a Precursor for Fluorinated Compounds:
3,3-Difluoro-4-hydroxypiperidine may be utilized as a precursor for the synthesis of other fluorinated compounds, which are important in various chemical and pharmaceutical applications due to the unique properties conferred by fluorine atoms.

Upstream product

• 1239596-53-2 N-benzyl-3,3-difluoro-4-hydroxypiperidine 
• 1067914-81-1 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol 
• 851314-55-1 ethyl N-[3-(ethyloxy)-2,2-difluoro-3-oxopropyl]-N-(phenylmethyl)-beta-alaninate 
• 1067915-34-7 ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate 
• 851314-56-2 ethyl 5,5-difluoro-4-hydroxy-1-(phenylmethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate 

Downstream Products

• 1209780-71-1 tert-butyl 3,3-difluoro-4-hydroxy-piperidine-1-carboxylate 
• 1215071-17-2 tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate 
• 1334412-95-1 tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylate 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 
• 1820679-70-6 (±)-tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate 
• 1067914-82-2 (±)-tert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate 

Relevant academic research and scientific papers

5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER

The present invention discloses 5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The 5-substituted difluoropiperidine compounds, derivatives

SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

The present invention discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The quinazoline compounds, derivatives and pharmaceutically acceptabl

Quinazoline derivative salt-type crystal forms and preparation method and application thereof

The invention discloses quinazoline derivative salt-type crystal forms and a preparation method and application thereof. The quinazoline derivative salt-type crystal forms are specifically the hydrochloride crystal forms A, B, C, D, F, H, I, the sulphate

PIPERIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Bridged Spiro[2.4]heptane Ester Derivatives

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a cata

FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), wherein n and R1 are as defined in the description, their preparation and their pharmaceutically active compounds.

BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES

The present invention relates to bridged spiro[2.4]heptane ester derivatives of formula (I) wherein W, Y, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.